President of AstraZeneca, Pascal Soriot He informed Nadia Calviño, First Vice President and Minister of Economic Affairs and Digital Transformation, that the pharmaceutical company plans to hire 1,000 more people in Spain by 2025 as part of its investment plans.
The announcement was made as part of a corporate visit by Soriot’s company president in Spain. Rick R. Suarez. In particular, the company disclosed data and investment plans in Spain until 2025, demonstrating its global commitment to increase investment in the country “as a global engine of R&D growth”.
AstraZeneca in Spain invests in 2021 more than 93 million euros In innovative projects, 48 million of which are allocated to R&D. The entire commitment of AstraZeneca in Spain in 2022, alexionbringing the total investment to around €400m, more than four times the figure recorded a year ago.
In terms of workforce, AstraZeneca increased its workforce by 20% in 2022, Reaching 1,300 employees, According to company plans, about 1,000 more will be added in the coming years. In terms of clinical trials, Spain hosted about 300, including over 4,500 patients in 2022.
“Online” with other billionaires
After the meeting, the first vice president underlined that AstraZeneca’s commitment will make creation possible. quality work and other billionaire investment announcements made in recent months by multinational companies from all industries.
“Spain is already leading the world in clinical trials and cutting-edge treatments,” stressed Calviño. New drugs “likely” to be launched in a few years personalized sensitivity in the context of public health. Likewise, the vice president emphasized that the pharmaceutical industry is “a key activity with high added value” due to its contribution to the knowledge economy in Spain.
Spanish R&D ecosystem
And according to Spanish R&D ecosystem Pascal Soriot “this is first class” Therefore, he promised to work with the Spanish Government to unlock the potential of innovative medicines as an “engine of long-term economic growth”.
“We will continue to invest in environments and expand our capabilities. committed to innovation and development“, stressed during his corporate visit.
The number was also shared at the meeting. clinical trials They will have history to date and in the near future, as well as the increase in the number of patients accessing innovation in key areas of the company, such as oncology, cardiovascular, renal and metabolic diseases, respiratory diseases, vaccines and immunotherapies, and rare diseases and their projection.
Currently, the company has 179 clinical development programs. 15 of them are in the most advanced stages of study. “AstraZeneca is reinforcing its commitment to research and innovation as well as improving the availability of new drugs with new projects in Spain,” said Rick R.
Suárez is committed to the company’s global “strengthening health systems and fair and affordable access for patients We ranked third in the 2020 Drug Access Index (AtMI).
Finally, both Soriot and Suárez stressed the importance of public-private collaborations, as in vaccine donation projects for the Covid-19 pandemic and other recent public and private initiatives such as the agreement between the company and the United States. Vall d’Hebron Oncology Institute (VHIO), to promote preclinical and translational research and the Partnership for Health System Sustainability and Resilience (PHSSR).
Finally, the company’s senior management also wanted to highlight its latest investment. €5.5 million in new offices and the Innovation Center in Madrid.